FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214770459> ?p ?o ?g. }

• W4214770459 abstract "Abstract Trials guidance: The Abstract should not exceed 350 words. Please minimize the use of abbreviations and do not cite references in the abstract. The abstract must include the following separate sections:• Background : Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Programme for use as the primary vaccination series. More than 90% of the Singapore population has received at least one dose of a COVID-19 vaccine as of December 2021. With the demonstration that vaccine effectiveness wanes in the months after vaccination, and the emergence of Omicron which evades host immunity from prior infection and/or vaccination, attention in many countries has shifted to how best to maintain immunity through booster vaccinations. • Methods : The objectives of this phase 3, randomized, subject-blinded, controlled clinical trial are to assess the safety and immunogenicity of heterologous boost COVID-19 vaccine regimens (intervention groups 1-4) compared with a homologous boost regimen (control arm) in up to 600 adult volunteers. As non-mRNA vaccine candidates may enter the study at different time points depending on vaccine availability and local regulatory approval, participants will be randomized at equal probability to the available intervention arms at the time of randomization. Eligible participants will have received two doses of a homologous mRNA vaccine series with BNT162b2 or mRNA-1273 at least six months prior to enrolment. Participants will be excluded if they have a history of confirmed SARS or SARS-CoV-2 infection, are immunocompromised or pregnant. Participants will be monitored for adverse events and serious adverse events by physical examinations, laboratory tests and self-reporting. Blood samples will be collected at serial time points [Pre-vaccination/screening (Day -14 to Day 0), Day 7, Day 28, Day 180, Day 360 post-vaccination] for assessment of antibody and cellular immune parameters. Primary endpoint is the level of anti-SARS-CoV-2 spike immunoglobulins at Day 28 post-booster, and will be measured against wildtype SARS-CoV-2 and variants of concern. Comprehensive immune profiling of the humoral and cellular immune response to vaccination will be performed. • Discussion : This study will provide necessary data to understand the quantity, quality and persistence of the immune response to homologous and heterologous third booster dose of COVID-19 vaccines. This an important step in developing COVID-19 vaccination programs beyond the primary series. Trial registration : ClinicalTrials.gov NCT05142319, registered on 2 Dec 2021." @default.
• W4214770459 created "2022-03-02" @default.
• W4214770459 creator A5004179895 @default.
• W4214770459 creator A5006587646 @default.
• W4214770459 creator A5013366445 @default.
• W4214770459 creator A5014540693 @default.
• W4214770459 creator A5016545803 @default.
• W4214770459 creator A5031060060 @default.
• W4214770459 creator A5039929987 @default.
• W4214770459 creator A5044578876 @default.
• W4214770459 creator A5049518482 @default.
• W4214770459 creator A5052831374 @default.
• W4214770459 creator A5054628481 @default.
• W4214770459 creator A5060133698 @default.
• W4214770459 creator A5072298339 @default.
• W4214770459 creator A5081970570 @default.
• W4214770459 creator A5091511364 @default.
• W4214770459 creator A5091813462 @default.
• W4214770459 date "2022-02-28" @default.
• W4214770459 modified "2023-10-01" @default.
• W4214770459 title "Evaluation of the Safety and Immunogenicity of Different COVID-19 Vaccine Combinations in Healthy Individuals: Study Protocol for a Randomized, Subject-blinded, Controlled Phase 3 Trial [PRIBIVAC]" @default.
• W4214770459 doi "https://doi.org/10.21203/rs.3.rs-1326528/v1" @default.
• W4214770459 hasPublicationYear "2022" @default.
• W4214770459 type Work @default.
• W4214770459 citedByCount "0" @default.
• W4214770459 crossrefType "posted-content" @default.
• W4214770459 hasAuthorship W4214770459A5004179895 @default.
• W4214770459 hasAuthorship W4214770459A5006587646 @default.
• W4214770459 hasAuthorship W4214770459A5013366445 @default.
• W4214770459 hasAuthorship W4214770459A5014540693 @default.
• W4214770459 hasAuthorship W4214770459A5016545803 @default.
• W4214770459 hasAuthorship W4214770459A5031060060 @default.
• W4214770459 hasAuthorship W4214770459A5039929987 @default.
• W4214770459 hasAuthorship W4214770459A5044578876 @default.
• W4214770459 hasAuthorship W4214770459A5049518482 @default.
• W4214770459 hasAuthorship W4214770459A5052831374 @default.
• W4214770459 hasAuthorship W4214770459A5054628481 @default.
• W4214770459 hasAuthorship W4214770459A5060133698 @default.
• W4214770459 hasAuthorship W4214770459A5072298339 @default.
• W4214770459 hasAuthorship W4214770459A5081970570 @default.
• W4214770459 hasAuthorship W4214770459A5091511364 @default.
• W4214770459 hasAuthorship W4214770459A5091813462 @default.
• W4214770459 hasBestOaLocation W42147704591 @default.
• W4214770459 hasConcept C12590561 @default.
• W4214770459 hasConcept C126322002 @default.
• W4214770459 hasConcept C168563851 @default.
• W4214770459 hasConcept C187212893 @default.
• W4214770459 hasConcept C203014093 @default.
• W4214770459 hasConcept C22070199 @default.
• W4214770459 hasConcept C2779134260 @default.
• W4214770459 hasConcept C2780801004 @default.
• W4214770459 hasConcept C2780868878 @default.
• W4214770459 hasConcept C2781413609 @default.
• W4214770459 hasConcept C2908647359 @default.
• W4214770459 hasConcept C3008058167 @default.
• W4214770459 hasConcept C512399662 @default.
• W4214770459 hasConcept C524204448 @default.
• W4214770459 hasConcept C535046627 @default.
• W4214770459 hasConcept C71924100 @default.
• W4214770459 hasConcept C8891405 @default.
• W4214770459 hasConcept C89623803 @default.
• W4214770459 hasConcept C99454951 @default.
• W4214770459 hasConceptScore W4214770459C12590561 @default.
• W4214770459 hasConceptScore W4214770459C126322002 @default.
• W4214770459 hasConceptScore W4214770459C168563851 @default.
• W4214770459 hasConceptScore W4214770459C187212893 @default.
• W4214770459 hasConceptScore W4214770459C203014093 @default.
• W4214770459 hasConceptScore W4214770459C22070199 @default.
• W4214770459 hasConceptScore W4214770459C2779134260 @default.
• W4214770459 hasConceptScore W4214770459C2780801004 @default.
• W4214770459 hasConceptScore W4214770459C2780868878 @default.
• W4214770459 hasConceptScore W4214770459C2781413609 @default.
• W4214770459 hasConceptScore W4214770459C2908647359 @default.
• W4214770459 hasConceptScore W4214770459C3008058167 @default.
• W4214770459 hasConceptScore W4214770459C512399662 @default.
• W4214770459 hasConceptScore W4214770459C524204448 @default.
• W4214770459 hasConceptScore W4214770459C535046627 @default.
• W4214770459 hasConceptScore W4214770459C71924100 @default.
• W4214770459 hasConceptScore W4214770459C8891405 @default.
• W4214770459 hasConceptScore W4214770459C89623803 @default.
• W4214770459 hasConceptScore W4214770459C99454951 @default.
• W4214770459 hasLocation W42147704591 @default.
• W4214770459 hasOpenAccess W4214770459 @default.
• W4214770459 hasPrimaryLocation W42147704591 @default.
• W4214770459 hasRelatedWork W2029074520 @default.
• W4214770459 hasRelatedWork W2040482600 @default.
• W4214770459 hasRelatedWork W2095477718 @default.
• W4214770459 hasRelatedWork W2466910529 @default.
• W4214770459 hasRelatedWork W2993867188 @default.
• W4214770459 hasRelatedWork W4226061695 @default.
• W4214770459 hasRelatedWork W4319741939 @default.
• W4214770459 hasRelatedWork W4321437469 @default.
• W4214770459 hasRelatedWork W4362640123 @default.
• W4214770459 hasRelatedWork W4365443543 @default.
• W4214770459 isParatext "false" @default.
• W4214770459 isRetracted "false" @default.
• W4214770459 workType "article" @default.